ARQT

SEC source: 0001209191-20-006599 · doc4.xml · derivative · entry 3

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,486 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

SEC source: 0001209191-20-006599 · doc4.xml · nonDerivative · entry 2

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 49,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The securities are held of record by The Chaudhuri Family Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-006599 · doc4.xml · nonDerivative · entry 1

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

SEC source: 0001209191-20-006595 · doc4.xml · derivative · entry 4

OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,991 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

SEC source: 0001209191-20-006595 · doc4.xml · nonDerivative · entry 1

OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

SEC source: 0001209191-20-006603 · doc4.xml · derivative · entry 3

Welgus Howard G. · CIK 0001801050 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 24,991 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-006603 · doc4.xml · nonDerivative · entry 1

Welgus Howard G. · CIK 0001801050 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 24,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-006601 · doc4.xml · derivative · entry 7

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By LLC

Disclosed balance after: 0

Underlying: Common Stock · 49,981 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-006601 · doc4.xml · derivative · entry 6

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 99,964 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

SEC source: 0001209191-20-006601 · doc4.xml · nonDerivative · entry 2

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By LLC

Disclosed balance after: 49,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-006601 · doc4.xml · nonDerivative · entry 1

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 478,447

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

SEC source: 0000899243-20-003487 · doc4.xml · derivative · entry 5

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 859,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F3 · ownership.nature: Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

SEC source: 0000899243-20-003487 · doc4.xml · derivative · entry 4

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,825,602 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F2 · ownership.nature: Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

SEC source: 0000899243-20-003487 · doc4.xml · nonDerivative · entry 3

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,979,292

F4 · ownership.nature: Represents 266,807 and 27,310 shares of Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

SEC source: 0000899243-20-003487 · doc4.xml · nonDerivative · entry 2

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,685,175

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F3 · ownership.nature: Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

SEC source: 0000899243-20-003487 · doc4.xml · nonDerivative · entry 1

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,825,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F2 · ownership.nature: Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

SEC source: 0001209191-20-007100 · doc4.xml · derivative · entry 7

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,074,467 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007100 · doc4.xml · derivative · entry 6

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,099,019 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007100 · doc4.xml · derivative · entry 5

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,360,272 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 4

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,542,790

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 3

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,042,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 2

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,968,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 1

Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner

FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner

FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,869,304

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · derivative · entry 7

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,074,467 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · derivative · entry 6

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,099,019 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · derivative · entry 5

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 6,360,272 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · nonDerivative · entry 4

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 10,542,790

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · nonDerivative · entry 3

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 10,042,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · nonDerivative · entry 2

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 8,968,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-007104 · doc4.xml · nonDerivative · entry 1

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Frazier Life Sciences VIII, L.P.

Disclosed balance after: 6,869,304

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000947871-20-000079 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 176,500

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in the Issuer's initial public offering.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPMF.

SEC source: 0000947871-20-000079 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 382,388

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in the Issuer's initial public offering.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000078 · ownership.xml · nonDerivative · entry 2

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 176,500

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in the Issuer's initial public offering.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPMF.

SEC source: 0000947871-20-000078 · ownership.xml · nonDerivative · entry 1

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 382,388

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in the Issuer's initial public offering.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-006135 · doc4.xml · derivative · entry 1

TURNER JOSEPH L · CIK 0001266129 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2030-01-30

F1 · date: Stock options were granted to the Reporting Person on January 30, 2020 in connection with the Reporting Person's appointment to the Issuer's Board of Directors on January 30, 2020.

F2 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of January 30, 2021, January 30, 2022 and January 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.